Respiratory Drugs - Global Strategic Business Report

This report analyzes the worldwide markets for Respiratory Drugs in US$ Million. The major product segments analyzed are Asthma, Allergic Rhinitis, and COPD (Chronic Obstructive Pulmonary Disease). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 69 companies including many key and niche players worldwide such as Accentia Biopharmaceuticals, Inc., Aerogen, Inc., Aerovance, Inc., airPharma, AstraZeneca, Aventis Pharma Limited, Bespak, Boehringer Ingelheim Pharmaceuticals, Inc., Cadila Pharmaceuticals, Dr. Reddys Laboratories, EvoGenix, GlaxoSmithKline, GlaxoSmithKline Pharmaceuticals Ltd., Inyx, Inc., The Merck Generics Group, Novartis AG, Pfizer, Inc., Ranbaxy Laboratories Limited, Respironics, Inc., Sandoz International GmbH, and Schering-Plough Corp.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying

RESPIRATORY DRUGS MCP-1577
A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II.
1. Market Overview II-1
Respiratory Diseases
Common and Serious II-1
Rhinoviruses
Root Cause of Major Respiratory Diseases II-1
Leading Asthmatic Drugs and their Patent Expiries II-2
Antihistamine or Allergic Rhinitis Market II-2
Leading Anti-Allergy Drugs and Patent Expiry Years II-3
Current and Future Analysis II-3
Regional Perspective II-3
Product Segment Perspective II-3

2. Common Respiratory Diseases
Overview II-4
Influenza II-4
Asthma II-4
Factors Promoting Asthma II-5
Treatment II-5
Respiratory Distress Syndrome (RDS) II-5
Symptoms II-6
Complications Related to RDS II-6
Analysis of RDS II-6
Alternative Methods for the Treatment of RDS II-7
Preventive Measures II-7
Chronic Obstructive Pulmonary Disease II-8
Characteristics and Symptoms of COPD II-8
Risks Associated with COPD II-8
Bronchitis II-9
Respiratory Syncytial Virus (RSV) II-9

3. Treatment of Respiratory Diseases
An Overview II-10
Respiratory Therapy with Information Technology II-10
Antiviral Drugs for Controlling Influenza and RSV Infections II-10
Pulmonary Drug Delivery II-10
Why are Lungs Considered a Good Alternative? II-10
COPD
Taking a Toll on Human Lives II-11
Upper Respiratory Tract Infections (URIs) II-11
Respiratory Failure Management II-11
CPAP: Non-Invasive Respiration II-12
Face Masks: Carriers of Oxygen Therapy II-12
Endotracheal Intubation and Ventilatory Support II-12
Endotracheal Intubation Turns Perilous II-13
Ventilator Strategy II-13
Methods of Ventilation II-14
Weaning from the Ventilator II-15
Respiratory Support: A Broader Perspective II-15
Humidification II-15
Posture II-15
Physiotherapy II-15
Pharmacological Adjuncts II-15
Sedation II-16
New Drugs, Treatments Ease Life of Patients with Respiratory
Problems II-16
Progesterone II-16
Partial Liquid Ventilation II-17
Heliox II-17
High-level PREP II-18
Respiratory Failure II-18
Types of Respiratory Failure II-19
Factors Leading to Respiratory Failure II-19
Blockage of air passage II-19
Drug abuse or alcohol addiction II-19
Obesity II-19
Muscle weakness II-19
Lung disorders and diseases II-19
Abnormalities in Chest Walls II-19
Cellular Disorders II-19
Treatment for Respiratory Failure II-20
Role of Health Care Teams II-20
Long-Term Consequences of Respiratory Failures II-21
Preventive Measures II-21
Measures to Prevent the Recurrence of Respiratory Diseases II-21
Telithromycin: Treatment for Respiratory Disorders II-21
Consequences of Telithromycin II-22

4. Recent Industry Activity II-23
Arcadia Resources, Inc Acquires Remedy Therapeutics, L.L.C II-23
Sirna Forms Alliance with GlaxoSmithKline II-23
Pharmaxis Ltd and Nigaard Pharma Enters into Distribution
Agreement II-23
Teva Regains Leadership Position through Ivax Acquisition II-23
AstraZeneca Submits Symbicort for US FDA Approval II-24
Ranbaxy Laboratories Receives FDA Approval II-24
Innovata Inks Development Agreement for Duohaler II-24
Novartis Obtains License from Arrow Therapeutics for A60444
Molecule Inhibitor II-24
Arakis Ltd and Vectura Group plc Initiate Phase IIb Clinical
Trial of NVA237 II-25
Schering-Plough Receives FDA Approval for Asmanex II-25
Isis Pharmaceuticals Develops ISIS 369645 II-25
Inyx Acquires Celltech Manufacturing Services from UCB II-25
Ashton Pharmaceuticals Partners with Innovata and Merck II-25
King Pharmaceuticals Collaborates with Inyx II-26
Inyx Pharma Ltd. Bags a Contract from Generics II-26
Alnylam Pharmaceuticals Initiates Phase I Trials on ALN-RSV01 II-27
MAP and Elan Extend their Agreement for Developing Advanced
Version of Asthma Drug II-27
Accentia Enters into Licensing Agreement with Collegium II-27
Novartis Inks Agreement with Arakis and Vectura II-28
Pfizer and Rigel Sign Collaborative Agreement II-28
NicOx Enters into Developing and Licensing Agreement with
Topigen II-29
Merck to Strike a Licensing Deal with Innovata for Developing
Respiratory Medicines II-29
Lannett Receives Approval from FDA for the Distribution of
Terbutaline Sulfate Tablets II-30
GlaxoSmithKline Licenses Inhaled Respiratory Therapy from
Theravance II-30
Novartis’ Sandoz Completes Acquisition of Hexal AG II-31
Sandoz Acquires Eon Labs II-31
SkyePharma, PLC Enters into License Agreement with
GlaxoSmithKline II-31
Kos Pharmaceuticals Signs Agreement with Aventis Pharmaceuticals II-31
US FDA Approves New Antibiotic, Ketek II-31
Zambon Terminates Single-Agent Inhaler Project II-32
Boehringer Ingelheim Pharmaceuticals Obtains FDA Approval for
Atrovent HFA II-32
Ranbaxy Receives FDA Approval for Loratadine and
Pseudoephedrine Sulfate Tablets II-32
Lincoln Pharmaceuticals Limited Introduces Gatilink, an
Antibiotic II-32
GlaxoSmithKline Forms Alliance with Theravance II-33
Etiologics Acquires Bayer’s Pre-clinical Respiratory Research
Group II-33
IVAX Pharmaceutical Signs Pan-European Agreement with 3M II-33
GlaxoSmithKline Inks Agreement with Theravance II-33
Cadila Pharmaceuticals Ltd Launches Montelast for Asthma II-33
Alpharma Unveils Generic Loratadine Syrup II-33
Dr. Reddy’s Laboratories Launches Brancho-Vaxom II-33

5. Focus on Select Players II-34
Accentia Biopharmaceuticals, Inc. (US) II-34
Aerogen, Inc. (US) II-34
Aerovance, Inc (US) II-34
airPharma (US) II-34
AstraZeneca (UK) II-35
Aventis Pharma Limited (India) II-35
Bespak (UK) II-35
Boehringer Ingelheim Pharmaceuticals, Inc (Germany) II-35
Cadila Pharmaceuticals (India) II-35
Dr. Reddys Laboratories (India) II-36
EvoGenix (Australia) II-36
GlaxoSmithKline (US) II-37
GlaxoSmithKline Pharmaceuticals Ltd. (India) II-37
Inyx, Inc. (US) II-37
The Merck Generics Group (Germany) II-37
Novartis AG (Switzerland) II-38
Pfizer, Inc. (US) II-38
Ranbaxy Laboratories Limited (India) II-39
Respironics, Inc (US) II-40
Sandoz International GmbH (Germany) II-40
Schering-Plough Corp (US) II-41

6. Global Market Perspective II-42
Table 1: Recent Past, Current and Future Analysis for
Respiratory Drugs by Geographic Region
US, Canada, Japan,
Europe and Rest of World Markets Independently Analyzed by
Annual Sales in US$ Million for the Years 2000 through 2010
(includes corresponding Graph/Chart) II-42

Table 2: World 10-Year Perspective for Respiratory Drugs by
Geographic Region
Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe and Rest of World Markets for the
Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-42

Table 3: World Recent Past, Current and Future Analysis for
Asthma Drugs by Geographic Region
US, Canada, Japan, Europe
and Rest of World Markets Independently Analyzed by Annual
Sales in US$ Million for the Years 2000 through 2010
(includes corresponding Graph/Chart) II-43

Table 4: World 10-Year Perspective for Asthma Drugs by
Geographic Region
Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe and Rest of World Markets for the
Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-43

Table 5: World Recent Past, Current and Future Analysis for
Allergic Rhinitis Drugs by Geographic Region
US, Canada,
Japan, Europe and Rest of World Markets Independently Analyzed
by Annual Sales in US$ Million for the Years 2000 through
2010 (includes corresponding Graph/Chart) II-44

Table 6: World 10-Year Perspective for Allergic Rhinitis
Drugs by Geographic Region
Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe and Rest of World Markets
for the Years 2000, 2006 and 2010 (includes corresponding
Graph/Chart) II-44

Table 7: World Recent Past, Current and Future Analysis for
Chronic Obstructive Pulmonary Disease (COPD) Drugs by
Geographic Region
US, Canada, Japan, Europe and Rest of
World Markets Independently Analyzed by Annual Sales in US$
Million for the Years 2000 through 2010 (includes
corresponding Graph/Chart) II-45

Table 8: World 10-Year Perspective for Chronic Obstructive
Pulmonary Disease (COPD) Drugs by Geographic Region -
Percentage Breakdown of Dollar Sales for US, Canada, Japan,
Europe and Rest of World Markets for the Years 2000, 2006 and
2010 (includes corresponding Graph/Chart) II-45

III. MARKET

1. The United States III-1
A.Market Analysis III-1
Current & Future Analysis III-1
Market Scenario III-1
Asthma III-1
COPD III-2
Leading Respiratory Drug Brands III-2
Strategic Corporate Developments III-2
Focus on Select Players III-8
B.Market Analytics III-11
Table 9: US Recent Past, Current and Future Analysis for
Respiratory Drugs by Product Segment
Asthma Drugs,
Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary
Disease (COPD) Drugs Independently Analyzed by Annual Sales
in US$ Million for the Years 2000 through 2010 (includes
corresponding Graph/Chart) III-11

Table 10: US 10-Year Perspective for Respiratory Drugs by
Product Segment
Percentage Breakdown of Dollar Sales for
Asthma Drugs, Allergic Rhinitis Drugs and Chronic
Obstructive Pulmonary Disease (COPD) Drugs for the Years
2000, 2006 and 2010 (includes corresponding Graph/Chart) III-11

2. Canada III-12
Market Analysis III-12
Table 11: Canadian Recent Past, Current and Future Analysis
for Respiratory Drugs by Product Segment
Asthma Drugs,
Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary
Disease (COPD) Drugs Independently Analyzed by Annual Sales
in US$ Million for the Years 2000 through 2010 (includes
corresponding Graph/Chart) III-12

Table 12: Canadian 10-Year Perspective for Respiratory Drugs
by Product Segment
Percentage Breakdown of Dollar Sales
for Asthma Drugs, Allergic Rhinitis Drugs and Chronic
Obstructive Pulmonary Disease (COPD) Drugs for the Years
2000, 2006 and 2010 (includes corresponding Graph/Chart) III-13

3. Japan III-14
Market Analysis III-14
Table 13: Japanese Recent Past, Current and Future Analysis
for Respiratory Drugs by Product Segment
Asthma Drugs,
Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary
Disease (COPD) Drugs Independently Analyzed by Annual Sales
in US$ Million for the Years 2000 through 2010 (includes
corresponding Graph/Chart) III-14

Table 14: Japanese 10-Year Perspective for Respiratory Drugs
by Product Segment
Percentage Breakdown of Dollar Sales
for Asthma Drugs, Allergic Rhinitis Drugs and Chronic
Obstructive Pulmonary Disease (COPD) Drugs for the Years
2000, 2006 and 2010 (includes corresponding Graph/Chart) III-15

4. Europe III-16
A.Market Analysis III-16
Current & Future Analysis III-16
Strategic Corporate Developments III-16
Focus on Select Players III-20
B.Market Analytics III-23
Table 15: European Recent Past, Current and Future Analysis
for Respiratory Drugs by Product Segment
Asthma Drugs,
Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary
Disease (COPD) Drugs Independently Analyzed by Annual Sales
in US$ Million for the Years 2000 through 2010 (includes
corresponding Graph/Chart) III-23

Table 16: European 10-Year Perspective for Respiratory Drugs
by Product Segment
Percentage Breakdown of Dollar Sales
for Asthma Drugs, Allergic Rhinitis Drugs and Chronic
Obstructive Pulmonary Disease (COPD) Drugs for the Years
2000, 2006 and 2010 (includes corresponding Graph/Chart) III-23

5. Rest of World III-24
A.Market Analysis III-24
Current & Future Analysis III-24
Strategic Corporate Developments III-24
Focus on Select Players III-25
B.Market Analytics III-29
Table 17: Rest of World Recent Past, Current and Future
Analysis for Respiratory Drugs by Product Segment
Asthma
Drugs, Allergic Rhinitis Drugs and Chronic Obstructive
Pulmonary Disease (COPD) Drugs Independently Analyzed by
Annual Sales in US$ Million for the Years 2000 through 2010
(includes corresponding Graph/Chart) III-29

Table 18: Rest of World 10-Year Perspective for Respiratory
Drugs by Product Segment
Percentage Breakdown of Dollar
Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic
Obstructive Pulmonary Disease (COPD) Drugs for the Years
2000, 2006 and 2010 (includes corresponding Graph/Chart) III-29
IV. COMPETITION
1. 3M Company (USA) IV-1
Table 19: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-4

Table 20: First Quarter Sales Analysis by Segment:
2005-2006 (In US$ million) IV-5

Table 21: Annual Sales Analysis: 2004-2005 (In US$
million) IV-5

Table 22: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-5

Table 23: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-5

Table 24: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-6
2. Accentia Biopharmaceuticals (USA) IV-15
Table 25: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-15

Table 26: Half Yearly Sales Analysis by Business
Segment: 2005-2006 (H1) (In US$ million) IV-16

Table 27: Half Yearly Sales Analysis by Quarter: 2005-
2006 (H1) (In US$ million) IV-16

Table 28: Annual Sales Analysis: 2004-2005 (In US$
million) IV-16

Table 29: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ million) IV-16

Table 30: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-16
3. Activaero GmbH (Germany) IV-20
4. Actavis (Iceland) IV-22
5. Acusphere, Inc. (USA) IV-26
Table 31: First Quarter Sales Analysis: 2005-2006 (In
US$ thousands) IV-27

Table 32: Annual Sales Analysis: 2004-2005 (In US$
thousands) IV-27
6. Aerovance, Inc. (USA) IV-28
7. Airpharma LLC (USA) IV-28
8. Alkermes, Inc. (USA) IV-29
Table 33: Annual Sales Analysis: 2004-2006 (In US$
million) IV-29
9. Alnylam Pharmaceuticals, Inc. (USA) IV-31
Table 34: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-31

Table 35: Annual Sales Analysis: 2004-2005 (In US$
million) IV-31

Table 36: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-32
10. Altana AG (Germany) IV-33
Table 37: First Quarter Sales Analysis: 2005-2006 (In €
million) IV-33

Table 38: Annual Sales Analysis: 2004-2005 (In €
million) IV-34

Table 39: Annual Sales Analysis by Segment: 2004-2005
(In € million) IV-34
Altana Pharma Pvt., Ltd. (India) IV-34
11. Argenta Discovery Ltd. (UK) IV-35
12. Arrow Therapeutics (UK) IV-38
13. Ashton Pharmaceuticals Limited (UK) IV-38
14. Astrazeneca PLC (UK) IV-39
Table 40: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-41

Table 41: First Quarter Sales Analysis by Geographic
Region: 2005-2006 (In US$ million) IV-41

Table 42: Annual Sales Analysis: 2003-2005 (In US$
million) IV-42

Table 43: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-42
15. AtheroGenics, Inc. (USA) IV-51
16. Aurobindo Pharma Ltd. (India) IV-53
Table 44: Annual Sales Analysis: 2004-2005 (In INR
million) IV-53
17. Bespak PLC (UK) IV-58
Table 45: Annual Sales Analysis: 2004-2005 (In £
million) IV-58

Table 46: Annual Sales Analysis by Segment: 2004-2005
(In £ million) IV-59

Table 47: Annual Sales Analysis by Geographic Region:
2004-2005 (In £ million) IV-59
18. Boehringer Ingelheim GmbH (Germany) IV-61
Boehringer Ingelheim Pharmaceuticals, Inc. (Germany) IV-65
Boehringer Ingelheim Ltd. (Germany) IV-65
Nippon Boehringer Ingelheim Co., Ltd. (Japan) IV-66
19. Breath Limited (USA) IV-67
20. Cadila Pharmaceuticals Ltd. (India) IV-68
21. Cardinal Health, Inc. (USA) IV-72
Table 48: Nine Months Sales Analysis: 2005-2006 (Nine
Months Ended, March) (In US$ billion) IV-73

Table 49: Nine Months Sales Analysis by Segment: 2005-
2006 (Nine Months Ended, March) (In US$ billion) IV-74

Table 50: Annual Sales Analysis: 2004-2005 (In US$
billion) IV-74

Table 51: Annual Sales Analysis by Segment: 2004-2005
(In US$ billion) IV-74

Table 52: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ billion) IV-74

Table 53: Annual Sales Analysis by Quarter: 2004-2005
(In US$ billion) IV-75
22. Chrysalis Technologies (USA) IV-77
23. Cipla Limited (India) IV-78
24. Clement Clarke International Ltd. (UK) IV-81
25. Clininvent Research Pvt., Ltd. (India) IV-83
26. Collegium Pharmaceutical, Inc. (USA) IV-85
27. Cytopia Ltd. (Australia) IV-87
Table 54: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ thousand) IV-87
28. Direct-Haler A/S (Denmark) IV-88
29. Elan Pharmaceuticals (USA) IV-89
30. Epigenesis Pharmaceuticals (USA) IV-89
31. Evogenix Ltd. (Australia) IV-90
32. GlaxoSmithKline PLC (UK) IV-92
Table 55: Annual Sales Analysis: 2004-2005 (In £
million) IV-93

Table 56: Annual Sales Analysis by Segment: 2004-2005
(In £ million) IV-93
Glaxosmithkline Pharmaceuticals Limited (India) IV-101
33. Healthline Aerosol Medicine (USA) IV-102
34. Innovata PLC (UK) IV-103
Table 57: Annual Sales Analysis: 2004-2005 (In £
million) IV-103

Table 58: Annual Sales Analysis by Geographic Region:
2004-2005 (In £ million) IV-104
35. Inyx, Inc. (USA) IV-105
Table 59: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-106

Table 60: Annual Sales Analysis: 2004-2005 (In US$
million) IV-106
36. Isis Pharmaceuticals, Inc. (USA) IV-108
Table 61: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-108

Table 62: First Quarter Sales Analysis by Business
Segment: 2005-2006 (In US$ million) IV-109

Table 63: Annual Sales Analysis: 2004-2005 (In US$
million) IV-109

Table 64: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-109

Table 65: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ million) IV-109
37. King Pharmaceuticals, Inc. (USA) IV-112
Table 66: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-114

Table 67: First Quarter Sales Analysis by Segment:
2005-2006 (In US$ million) IV-114

Table 68: Annual Sales Analysis: 2004-2005 (In US$
million) IV-115

Table 69: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-115
38. Kos Pharmaceuticals, Inc. (USA) IV-116
Table 70: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-117

Table 71: Annual Sales Analysis: 2004-2005 (In US$
million) IV-117
39. Lannett Company, Inc. (USA) IV-119
Table 72: Nine Months Sales Analysis: 2005-2006 (Nine
Months Ended, March) (In US$ million) IV-119

Table 73: Annual Sales Analysis: 2004-2005 (In US$
million) IV-119
40. Lincoln Pharmaceuticals Ltd. (India) IV-120
41. MAP Pharmaceuticals, Inc. (USA) IV-121
42. Markos Mefar SpA (Italy) IV-122
43. Merck KGAA (Germany) IV-123
Table 74: Annual Sales Analysis: 2003-2005 (In €
million) IV-125

Table 75: Annual Sales Analysis by Segment: 2004-2005
(In € million) IV-125
Merck Generics Group (Germany) IV-129
44. Nektar Therapeutics (USA) IV-130
Table 76: Annual Sales Analysis: 2004-2005 (In US$
million) IV-131
45. Nic Ox SA (France) IV-133
46. Nigaard Pharma AS (Norway) IV-135
47. Novartis AG (Switzerland) IV-136
Table 77: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-139

Table 78: First Quarter Sales Analysis by Segment:
2005-2006 (In US$ million) IV-140

Table 79: Annual Sales Analysis: 2004-2005 (In US$
million) IV-140

Table 80: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-140

Table 81: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-140
Sandoz Deutschland GmbH (Germany) IV-146
48. OM Pharma (Switzerland) IV-147
49. Oriel Therapeutics, Inc. (USA) IV-148
50. Pall Corporation (USA) IV-149
Table 82: Nine Months Sales Analysis: 2005-2006 (Nine
Months Ended, April) (In US$ million) IV-151

Table 83: Nine Months Sales Analysis by Business
Segment: 2005-2006 (Nine Months Ended, April) (In US$
million) IV-151

Table 84: Nine Months Sales Analysis by Geographic
Region: 2005-2006 (Nine Months Ended, April) (In US$
million) IV-151

Table 85: Annual Sales Analysis: 2004-2005 (In US$
million) IV-151

Table 86: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ million) IV-152

Table 87: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-152
51. PDL Biopharma, Inc. (USA) IV-155
Table 88: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-156

Table 89: Annual Sales Analysis: 2004-2005 (In US$
million) IV-156

Table 90: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-156
52. Pfizer, Inc. (USA) IV-159
53. Pharmaxis Ltd. (Australia) IV-173
54. Profile Therapeutics (UK) IV-174
55. Ranbaxy Laboratories Ltd. (India) IV-175
56. Respirics, Inc. (USA) IV-188
57. Respironics, Inc. (USA) IV-189
Table 91: Nine Months Sales Analysis: 2005-2006 (Nine
Months Ended, March) (In US$ million) IV-190

Table 92: Nine Months Sales Analysis by Quarter: 2005-
2006 (Nine Months Ended, March) (In US$ million) IV-190

Table 93: Annual Sales Analysis: 2004-2005 (In US$
million) IV-190

Table 94: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-191

Table 95: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-191

Table 96: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-191
58. Rigel Pharmaceuticals, Inc. (USA) IV-192
Table 97: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-192

Table 98: Annual Sales Analysis: 2004-2005 (In US$
million) IV-193

Table 99: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-193
59. Roche Holding AG (Switzerland) IV-194
60. Sanofi-Aventis (France) IV-195
Table 100: First Quarter Sales Analysis: 2005-2006 (In
€ million) IV-196

Table 101: Annual Sales Analysis: 2004-2005 (In €
million) IV-196

Table 102: Annual Sales Analysis by Segment: 2004-2005
(In € million) IV-196

Table 103: Annual Sales Analysis by Geographic Region:
2004-2005 (In € million) IV-196
Aventis Pharma Ltd. (India) IV-201
61. Schering-Plough Corporation (USA) IV-202
Table 104: Annual Sales Analysis: 2004-2005 (In US$
million) IV-203

Table 105: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-203

Table 106: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-203

Table 107: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-204
62. Sirna Therapeutics, Inc. (USA) IV-207
Table 108: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-208

Table 109: First Quarter Sales Analysis by Business
Segment: 2005-2006 (In US$ million) IV-208

Table 110: Annual Sales Analysis: 2004-2005 (In US$
million) IV-208
63. Sosei Co., Ltd. (Japan) IV-211
Table 111: Annual Sales Analysis: 2005-2006 (In ¥
million) IV-211

Table 112: Annual Sales Analysis: 2004-2005 (In ¥
million) IV-211
64. Teva Pharmaceutical Industries Ltd. (Israel) IV-214
Teva Pharmaceuticals USA (USA) IV-223
65. Theravance, Inc. (USA) IV-224
Table 113: Annual Sales Analysis: 2004-2005 (In US$
million) IV-224

Table 114: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-225
66. Topigen Pharmaceuticals, Inc. (Canada) IV-226
67. UCB S.A. (Belgium) IV-227
Table 115: Annual Sales Analysis: 2004-2005 (In €
million) IV-227

Table 116: Annual Sales Analysis by Business Segment:
2004-2005 (In € million) IV-227
68. Vectura Group PLC (UK) IV-231
Table 117: Annual Sales Analysis: 2004-2005 (In £
million) IV-231

Table 118: Annual Sales Analysis by Geographic Region:
2004-2005 (In £ million) IV-231
69. Zambon SpA (Italy) IV-234

The Companies Mentioned inside this Report include:

M Company (USA)
Accentia Biopharmaceuticals (USA)
Activaero GmbH (Germany)
Actavis (Iceland)
Acusphere, Inc (USA)
Aerovance, Inc (USA)
Airpharma LLC (USA)
Alkermes, Inc (USA)
Alnylam Pharmaceuticals, Inc (USA)
Altana AG (Germany)
Altana Pharma Pvt, Ltd (India)
Argenta Discovery Ltd (UK)
Arrow Therapeutics (UK)
Ashton Pharmaceuticals Limited (UK)
Astrazeneca PLC (UK)
AtheroGenics, Inc (USA)
Aurobindo Pharma Ltd (India)
Bespak PLC (UK)
Boehringer Ingelheim GmbH (Germany)
Boehringer Ingelheim Pharmaceuticals, Inc (Germany)
Boehringer Ingelheim Ltd (Germany)
Nippon Boehringer Ingelheim Co, Ltd (Japan)
Breath Limited (USA)
Cadila Pharmaceuticals Ltd (India)
Cardinal Health, Inc (USA)
Chrysalis Technologies (USA)
Cipla Limited (India)
Clement Clarke International Ltd (UK)
Clininvent Research Pvt, Ltd (India)
Collegium Pharmaceutical, Inc (USA)
Cytopia Ltd (Australia)
Table : Half Yearly Sales Analysis: - (H)
(In US$ thousand)
Direct-Haler A/S (Denmark)
Elan Pharmaceuticals (USA)
Epigenesis Pharmaceuticals (USA)
Evogenix Ltd (Australia)
GlaxoSmithKline PLC (UK)
Glaxosmithkline Pharmaceuticals Limited (India)
Healthline Aerosol Medicine (USA)
Innovata PLC (UK)
Inyx, Inc (USA)
Isis Pharmaceuticals, Inc (USA)
King Pharmaceuticals, Inc (USA)
Kos Pharmaceuticals, Inc (USA)
Lannett Company, Inc (USA)
Lincoln Pharmaceuticals Ltd (India)
MAP Pharmaceuticals, Inc (USA)
Markos Mefar SpA (Italy)
Merck KGAA (Germany)
Merck Generics Group (Germany)
Nektar Therapeutics (USA)
Nic Ox SA (France)
Nigaard Pharma AS (Norway)
Novartis AG (Switzerland)
Sandoz Deutschland GmbH (Germany)
OM Pharma (Switzerland)
Oriel Therapeutics, Inc (USA)
Pall Corporation (USA)
PDL Biopharma, Inc (USA)
Pfizer, Inc (USA)
Pharmaxis Ltd (Australia)
Profile Therapeutics (UK)
Ranbaxy Laboratories Ltd (India)
Respirics, Inc (USA)
Respironics, Inc (USA)
Rigel Pharmaceuticals, Inc (USA)
Roche Holding AG (Switzerland)
Sanofi-Aventis (France)
Aventis Pharma Ltd (India)
Schering-Plough Corporation (USA)
Sirna Therapeutics, Inc (USA)
Sosei Co, Ltd (Japan)
Teva Pharmaceutical Industries Ltd (Israel)
Teva Pharmaceuticals USA (USA)
Theravance, Inc (USA)
Topigen Pharmaceuticals, Inc (Canada)
UCB SA (Belgium)
Vectura Group PLC (UK)
Zambon SpA (Italy)